These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 18182278)

  • 21. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
    Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
    Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.
    Novak RM; Chen L; MacArthur RD; Baxter JD; Huppler Hullsiek K; Peng G; Xiang Y; Henely C; Schmetter B; Uy J; van den Berg-Wolf M; Kozal M;
    Clin Infect Dis; 2005 Feb; 40(3):468-74. PubMed ID: 15668873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
    Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
    J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human immunodeficiency virus-1 genotypic drug resistance among volunteer blood donors in Yunnan, China.
    Tu YQ; Wang MJ; Yao J; Zhu XM; Pan PL; Xing WG; Zhang GH; Yang RG; Zheng YT; Jiang Y
    Transfusion; 2009 Sep; 49(9):1865-73. PubMed ID: 19453981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease.
    Adekale MA; Cane PA; McCrae MA
    J Med Virol; 2005 Feb; 75(2):195-201. PubMed ID: 15602725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
    J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
    Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
    J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil.
    Cardoso LP; Pereira GA; Viegas AA; Schmaltz LE; Stefani MM
    J Med Virol; 2010 Mar; 82(3):351-7. PubMed ID: 20087934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil.
    Rodrigues R; Scherer LC; Oliveira CM; Franco HM; Sperhacke RD; Ferreira JL; Castro SM; Stella IM; Brigido LF
    Virus Res; 2006 Mar; 116(1-2):201-7. PubMed ID: 16332398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China.
    Zhao B; Han X; Dai D; Liu J; Ding H; Xu J; Chu Z; Bice T; Diao Y; Shang H
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1047-53. PubMed ID: 21417755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile.
    Ríos M; Delgado E; Pérez-Alvarez L; Fernández J; Gálvez P; de Parga EV; Yung V; Thomson MM; Nájera R
    J Med Virol; 2007 Jun; 79(6):647-56. PubMed ID: 17457921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotypic resistance mutations in treatment-naïve and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance.
    Sukasem C; Churdboonchart V; Sirisidthi K; Riengrojpitak S; Chasombat S; Watitpun C; Piroj W; Tiensuwan M; Chantratita W
    Jpn J Infect Dis; 2007 Sep; 60(5):284-9. PubMed ID: 17881868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.
    de Mulder M; Yebra G; Navas A; Martin L; de Jose MI; Navarro ML; de Ory SJ; Gonzalez-Granado I; Mellado MJ; Ramos JT; Holguin A
    Pediatr Infect Dis J; 2012 Nov; 31(11):e213-21. PubMed ID: 22785049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.
    Vergne L; Stuyver L; Van Houtte M; Butel C; Delaporte E; Peeters M
    J Clin Virol; 2006 May; 36(1):43-9. PubMed ID: 16563858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004.
    Babic DZ; Zelnikar M; Seme K; Vandamme AM; Snoeck J; Tomazic J; Vidmar L; Karner P; Poljak M
    Virus Res; 2006 Jun; 118(1-2):156-63. PubMed ID: 16417938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.